Pioneering The Development of Novel Therapeutics Targeting Stress Support Pathways
Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules targeting stress support pathways in cancer and inflammation using our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform.
Learn More
Our Proprietary BEACON+ Platform
We have created our proprietary BEACON+ to unlock the biochemical roles of NAD+-utilizing enzymes and to discover and develop novel small molecule therapeutics.
Learn More
RBN-2397 – PARP7 Inhibitor
Developing our lead product candidate, RBN-2397, as a potent, selective and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors.
Learn More
January 30
Join our team of experts.
Find Out More